IRIDEX CORP Files Definitive Additional Proxy Materials
Ticker: IRIX · Form: DEFA14A · Filed: Jun 2, 2025 · CIK: 1006045
| Field | Detail |
|---|---|
| Company | Iridex Corp (IRIX) |
| Form Type | DEFA14A |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, corporate-governance
TL;DR
IRIDEX CORP dropped more proxy docs, check 'em out.
AI Summary
IRIDEX CORP filed definitive additional materials on June 2, 2025, related to its proxy statement. The filing is under Schedule 14A, indicating it's a proxy solicitation under the Securities Exchange Act of 1934. The company is based in Mountain View, California, and operates in the electromedical and electrotherapeutic apparatus industry.
Why It Matters
This filing provides updated or supplementary information to shareholders regarding matters to be voted on at a company meeting, impacting corporate governance and shareholder decisions.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement update and does not contain information suggesting immediate financial or operational risks.
Key Players & Entities
- IRIDEX CORP (company) — Registrant
- 1212 TERRA BELLA AVE (location) — Business Address
- MOUNTAIN VIEW (location) — City
- CA (location) — State
- 94043 (location) — ZIP Code
FAQ
What type of filing is this?
This is a DEFA14A filing, which signifies Definitive Additional Materials for a proxy statement.
Who is the filing company?
The filing company is IRIDEX CORP.
When was this filing made?
The filing was made on June 2, 2025.
What is the company's primary business address?
The company's business address is 1212 Terra Bella Ave, Mountain View, CA 94043.
Under which SEC Act is this filing made?
This filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 2, 2025 regarding IRIDEX CORP (IRIX).